Kathryn Henderson, MD
Internal Medicine · Saint Louis, MONPI 1962630434
Payments from drug & device makers
Across 211 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$470
- Novo Nordisk$414
- AbbVie$387
- Lilly USA, LLC$315
- Amgen$226
- AstraZeneca$222
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,483100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 37 | $470 |
| Novo Nordisk | 31 | $414 |
| AbbVie | 14 | $387 |
| Lilly USA, LLC | 14 | $315 |
| Amgen | 14 | $226 |
| AstraZeneca | 15 | $222 |
| E.r. Squibb & Sons, L.L.C. | 13 | $211 |
| GSK | 11 | $193 |
| Johnson & Johnson | 9 | $157 |
| Sanofi-aventis U.S. LLC | 9 | $156 |
| Amarin Pharma, Inc. | 8 | $117 |
| Abbott | 5 | $92 |
| Exact Sciences | 3 | $66 |
| Astellas Pharma US Inc | 4 | $61 |
| Bayer | 3 | $51 |
| Inspire Medical Systems, Inc. | 1 | $48 |
| Novartis | 3 | $47 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Merck | 3 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Boehringer Ingelheim | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
How this compares
$3,483 in reported general payments places this provider in the 85th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 221 | $190,848 |
| OzempicSemaglutide | 131 | $149,577 |
| MounjaroTirzepatide | 103 | $113,202 |
| XareltoRivaroxaban | 60 | $62,657 |
| Breo ElliptaFluticasone/Vilanterol | 121 | $57,504 |
| JardianceEmpagliflozin | 48 | $57,149 |
| ProliaDenosumab | 33 | $55,204 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $40,516 |
| MyrbetriqMirabegron | 45 | $35,337 |
| Spiriva RespimatTiotropium Bromide | 35 | $26,476 |
| JanuviaSitagliptin Phosphate | 20 | $26,422 |
| MultaqDronedarone Hcl | 12 | $25,068 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 32 | $23,363 |
| FarxigaDapagliflozin Propanediol | 26 | $20,280 |
| TrulicityDulaglutide | 17 | $19,442 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $470 | $190,848221 claims |
| Novo NordiskOzempic, Wegovy | $414 | $164,523143 claims |
| Lilly USA, LLCMounjaro, Trulicity | $315 | $132,643120 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Arexvy | $193 | $129,021252 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $28 | $95,833103 claims |
| Johnson & JohnsonXarelto | $157 | $62,65760 claims |
| AmgenProlia | $226 | $55,20433 claims |
| Astellas Pharma US IncMyrbetriq | $61 | $35,33745 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $222 | $29,01640 claims |
| MerckJanuvia | $38 | $26,42220 claims |
| Sanofi-aventis U.S. LLCMultaq | $156 | $25,06812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Saint Louis
- Michael ReschakSaint Louis$3.1M
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Hany SalamaSaint Louis$279K
- Lauren LevineSaint Louis$264K
- Brij VaidSaint Louis$213K
- Vinay KamatSaint Louis$191K
- Tracy NorfleetSaint Louis$132K
- Paul OlivoSaint Louis$98K
- Priyanka RavalSaint Louis$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.